Alnylam Pharmaceuticals (ALNY) has recently drawn attention after a period of weaker share performance, with the stock down about 15% over the past month and roughly 26% over the past 3 months. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results